Police & Firemen s Retirement System of New Jersey Takes $99,000 Position in Ginkgo Bioworks Holdings, Inc. $DNA

Police & Firemen s Retirement System of New Jersey acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 8,772 shares of the company’s stock, valued at approximately $99,000.

A number of other institutional investors have also recently added to or reduced their stakes in DNA. Bank of New York Mellon Corp raised its stake in shares of Ginkgo Bioworks by 14.4% during the first quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company’s stock valued at $150,000 after acquiring an additional 3,331 shares during the last quarter. CWM LLC increased its holdings in Ginkgo Bioworks by 667.6% in the first quarter. CWM LLC now owns 12,274 shares of the company’s stock valued at $70,000 after purchasing an additional 10,675 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Ginkgo Bioworks during the 1st quarter worth $587,000. GSA Capital Partners LLP acquired a new position in Ginkgo Bioworks during the 1st quarter worth about $733,000. Finally, US Bancorp DE grew its position in shares of Ginkgo Bioworks by 43.5% in the 1st quarter. US Bancorp DE now owns 6,302 shares of the company’s stock valued at $36,000 after buying an additional 1,911 shares during the last quarter. 78.63% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DNA. BTIG Research raised their price objective on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a research report on Monday, August 25th. Cowen restated a “buy” rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Wall Street Zen lowered shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $9.00.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks stock opened at $9.28 on Friday. The stock has a market capitalization of $561.97 million, a price-to-earnings ratio of -1.49 and a beta of 1.53. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.00 and a 52-week high of $17.58. The stock’s 50 day moving average price is $11.82 and its two-hundred day moving average price is $11.00.

Ginkgo Bioworks (NYSE:DNA) last released its earnings results on Thursday, November 6th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.21). The company had revenue of $38.84 million for the quarter, compared to analyst estimates of $38.95 million. Ginkgo Bioworks had a negative net margin of 188.00% and a negative return on equity of 51.15%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Steven P. Coen sold 5,609 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total transaction of $84,135.00. Following the transaction, the insider owned 5,503 shares of the company’s stock, valued at $82,545. This represents a 50.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 9.72% of the company’s stock.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.